Tripeptide antioxidant · Fact sheet
Glutathione
Also known as GSH · Reduced glutathione
Glutathione is an antioxidant made by the body. Small oral studies measured glutathione stores and skin pigmentation, but they do not establish broad detox, anti-aging, or disease-prevention benefits.
What is Glutathione?
Glutathione is made from three amino acids and participates in cellular antioxidant systems. Different forms and routes are not interchangeable evidence.
Benefits & claims
Skin appearance, energy, immune support, and detox claims are common interests. An increase in an antioxidant biomarker is not the same as a demonstrated health improvement.
What the evidence supports
- Oral supplementation increased measured glutathione stores in one randomized study.
- Pigmentation differences in the small skin trial were significant at only two of six measured sites. Broad wellness benefits remain unproven.
Research areas
- Glutathione stores
- Skin pigmentation
- Oxidative-stress biomarkers
Dosage & frequency
Human study contextAn oral study tested changes in glutathione stores. Those biomarker results do not establish an injectable wellness regimen.
Randomized oral supplementation study
54 nonsmoking adults
- Amount
- 250 or 1,000 mg in separate study groups
- Frequency
- Daily for six months
- Route studied or labeled
- Oral
Body glutathione stores were studied; clinical wellness benefit was not established.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Oral, liposomal, inhaled, and intravenous glutathione have different exposure and evidence.
Interactions & precautions
- FDA reports adverse events associated with unsuitable glutathione ingredients used in sterile compounding.
What is still unresolved
- Clinical benefit beyond biomarker changes, and repeated injectable safety, remain uncertain.
Side effects & risks
- Small oral trials provide limited information about uncommon or long-term adverse effects.
- FDA documented adverse events linked to endotoxin-contaminated compounded sterile products; oral findings cannot establish injectable safety.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Early human evidenceA 54-person trial measured glutathione stores over six months. A separate 60-person, four-week skin study found small and uneven pigmentation changes; neither establishes durable clinical wellness benefits.
Studies
54-adult randomized trial measuring biomarkers, not disease prevention.
60-person, four-week trial with site-dependent results.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 4 sourced accounts by reported effect.
Energy: reported experiences
Repeated insomnia without more daytime energy
An author described insomnia on several attempts and later clarified that they had not noticed more energy.
Reported use in this account
- Product
- Injectable product described as glutathione
- Amount
- 100 mg, 20 mg and 10 mg on separate attempts
- Frequency
- Not specified clearly
- Route
- Injection; type not stated
- Duration
- Not specified clearly
This injectable-product account cannot be generalized to oral supplements. Product contents and other causes of insomnia were not verified.
Read the original accountMarked fatigue after combined exposure
Another author described sudden pronounced fatigue and a brief unusual head sensation after glutathione, following MOTS-c earlier that day.
Reported use in this account
- Product
- Product described as glutathione
- Amount
- 200 mg
- Frequency
- One reported administration
- Route
- Not specified clearly
- Duration
- One reported administration
Other exposures described: MOTS-c, reported at 1 mg earlier that day
MOTS-c was reported earlier the same day, so attribution is unclear. The description does not establish an administration route, and neither product contents nor symptoms were independently verified.
Read the original accountSleep: reported experiences
Repeated insomnia without more daytime energy
An author described insomnia on several attempts and later clarified that they had not noticed more energy.
Reported use in this account
- Product
- Injectable product described as glutathione
- Amount
- 100 mg, 20 mg and 10 mg on separate attempts
- Frequency
- Not specified clearly
- Route
- Injection; type not stated
- Duration
- Not specified clearly
This injectable-product account cannot be generalized to oral supplements. Product contents and other causes of insomnia were not verified.
Read the original accountDigestion: reported experiences
Acute illness in a contaminated-product investigation
FDA described nausea, vomiting, chills and other symptoms in a seven-patient report; one person developed low blood pressure and breathing difficulty and was hospitalized.
Reported use in this account
- Product
- Compounded L-glutathione in the seven-patient FDA adverse-event report
- Amount
- 1,400 mg per patient
- Frequency
- One reported administration
- Route
- Intravenous
- Duration
- One infusion on January 9, 2019
FDA testing found excessive endotoxin in the investigated material. This is a product-contamination signal and cannot be generalized to oral glutathione.
Read the FDA investigationSkin: reported experiences
Perceived skin changes with oral use
A commenter described visible skin improvements after about a year of liposomal glutathione, while also using CoQ10.
Reported use in this account
- Product
- Oral liposomal glutathione pills
- Amount
- 700 mg
- Frequency
- Daily
- Route
- Oral
- Duration
- About one year
Other exposures described: CoQ10
No standardized skin assessment verifies the change. The comment's broader absorption and collagen claims are not adopted here.
Read the original accountSensory changes: reported experiences
Marked fatigue after combined exposure
Another author described sudden pronounced fatigue and a brief unusual head sensation after glutathione, following MOTS-c earlier that day.
Reported use in this account
- Product
- Product described as glutathione
- Amount
- 200 mg
- Frequency
- One reported administration
- Route
- Not specified clearly
- Duration
- One reported administration
Other exposures described: MOTS-c, reported at 1 mg earlier that day
MOTS-c was reported earlier the same day, so attribution is unclear. The description does not establish an administration route, and neither product contents nor symptoms were independently verified.
Read the original accountAcute illness: reported experiences
Acute illness in a contaminated-product investigation
FDA described nausea, vomiting, chills and other symptoms in a seven-patient report; one person developed low blood pressure and breathing difficulty and was hospitalized.
Reported use in this account
- Product
- Compounded L-glutathione in the seven-patient FDA adverse-event report
- Amount
- 1,400 mg per patient
- Frequency
- One reported administration
- Route
- Intravenous
- Duration
- One infusion on January 9, 2019
FDA testing found excessive endotoxin in the investigated material. This is a product-contamination signal and cannot be generalized to oral glutathione.
Read the FDA investigationNo clear change: reported experiences
Repeated insomnia without more daytime energy
An author described insomnia on several attempts and later clarified that they had not noticed more energy.
Reported use in this account
- Product
- Injectable product described as glutathione
- Amount
- 100 mg, 20 mg and 10 mg on separate attempts
- Frequency
- Not specified clearly
- Route
- Injection; type not stated
- Duration
- Not specified clearly
This injectable-product account cannot be generalized to oral supplements. Product contents and other causes of insomnia were not verified.
Read the original accountApproval status
Glutathione has no FDA-approved drug indication for the wellness uses discussed here. Supplement availability is not premarket FDA approval of effectiveness or safety.
Supplement research is not FDA drug approval
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Meaningful effects beyond antioxidant measurements
- Durability of skin changes
- Long-term safety and comparability across routes
Summary
Pigmentation differences in the small skin trial were significant at only two of six measured sites. Broad wellness benefits remain unproven.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedOral glutathione and body stores
54-adult randomized trial measuring biomarkers, not disease prevention.
- fdaFDA: glutathione sterile-product safety concerns
Adverse-event investigation involving contaminated compounded products.
- fdaFDA: what approval means for supplements
Dietary supplements are not approved by FDA for safety and effectiveness before marketing.